Dataset: Transcription profiling by array of rat liver after treatment with D-penicillamine
Idiosyncratic drug reactions (IDRs) cause significant morbidity and mortality. In an animal model of IDRs, 50-80% of Brown Norway rats...
Idiosyncratic drug reactions (IDRs) cause significant morbidity and mortality. In an animal model of IDRs, 50-80% of Brown Norway rats exposed to D-penicillamine develop an autoimmune syndrome after several weeks of treatment. The symptoms of the IDR are similar to that observed in humans who take D-penicillamine. The mechanism of this reaction is unknown, and no effective biomarkers have been identified to predict susceptibility. We postulate that cell stress caused by drugs is required to initiate the response. We used a highthroughput approach to identify factors that might represent danger signals by profiling hepatic gene expression 6 h after dosing with D-penicillamine (150 mg/kg). Our results show that the drug-treated animals cluster into two distinct groups. One group exhibits substantial expression changes relative to control animals. The most significantly altered transcripts have a role in stress, energy metabolism, acute phase response, and inflammation. We used quantitative reverse transcriptase polymerase chain reaction to measure transcript levels in liver biopsies of 33 rats and found that resistant animals cluster together. This 'resistant' cluster of animals contains 87.5% (7/8) resistant animals but only 48% (12/25) 'sensitive' animals. This separation is statistically significant at the p 0.01 level. Experiment Overall Design: Single-channel Affy arrays used to profile 4 control Brown Norway rats and 8 D-Penicillamine treated Brown Norway rats.
- Species:
- rat
- Samples:
- 12
- Source:
- E-GEOD-2825
- PubMed:
- 16097792
- Updated:
- Jun.26, 2015
- Registered:
- Jan.12, 2015
Sample | Dose | Compound |
---|---|---|
GSE2825GSM61807 | 0 | none |
GSE2825GSM61807 | 0 | none |
GSE2825GSM61807 | 0 | none |
GSE2825GSM61807 | 0 | none |
GSE2825GSM61811 | 150 | D-penicillamine |
GSE2825GSM61811 | 150 | D-penicillamine |
GSE2825GSM61811 | 150 | D-penicillamine |
GSE2825GSM61811 | 150 | D-penicillamine |
GSE2825GSM61811 | 150 | D-penicillamine |
GSE2825GSM61811 | 150 | D-penicillamine |
GSE2825GSM61811 | 150 | D-penicillamine |
GSE2825GSM61811 | 150 | D-penicillamine |